Notably, the emergence of KRAS G12C inhibitors - such as sotorasib and adagrasib - offers significant therapeutic potential; these agents are now approved for second-line use in advanced or metastatic NSCLC and highlight the importance of comprehensive molecular testing to guide therapy selection [34]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.